Caribou Biosciences, Inc. (CRBU)

Caribou Biosciences, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Caribou Biosciences, Inc. (CRBU) is a Biotechnology company based in US with a market capitalization of $163.6M. Revenue grew 11.7% year-over-year and free cash flow was negative at -$112.4M. This page tracks CRBU's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 147 employees · IPO Jul 23, 2021

Valuation

Valuation & price

$2.14as of May 17, 2026· -24.6% vs 52w high

P/E ratio

Latest-FY diluted EPS

1.34

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$2.82$2.14$1.46Jul 25Jan 26Jul 26
$1.3952-week range$2.84
Loading valuation history…

Fundamentals

Key fundamentals

$163.6M

Market cap

11.7%

Revenue growth (YoY)

67.3%

Gross margin

-$112.4M

Free cash flow (USD)

-$112.1M

Net debt

Net cash position

3.4%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20192025

$5.8M$11.2M

Free cash flow by year

20192025

-$32.9M-$112.4M

Gross margin by year

20212025

89.8%67.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJun 18, 2026Filing

    Annual Meeting Results

  • 8-K eventJun 11, 2026Filing

    Clinical Trial Data Announced

  • 8-K eventMay 7, 2026Filing

    Earnings Release

  • Quarterly reportMay 7, 2026Filing

    10-Q Filed

  • 8-K eventMar 31, 2026Filing

    Regulatory Designation Received

Questions

Frequently asked questions

What is Caribou Biosciences, Inc.'s market cap?

Caribou Biosciences, Inc. (CRBU) has a market capitalization of $163.6M.

What is CRBU's P/E ratio?

A meaningful P/E ratio is not available for CRBU — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CRBU's price-to-book (P/B) ratio?

CRBU trades at 1.34 times book value per share.

Are insiders buying CRBU stock?

SEC Form 4 filings show no open-market insider buys at Caribou Biosciences, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.